Ebuderda Gunay

Ebuderda Gunay

Auto-generated profile, based on publicly available information

Ebuderda Gunay

Department of Wild Animal Diseases and Ecology, Faculty of Veterinary Medicine, Istanbul University-Cerrahpasa, Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2026 in BMC Veterinary Research
Verified
Journal Article
Open access
PDF file
YGYigit Gunes
Yigit Gunes
EGEbuderda Gunay
Ebuderda Gunay
NYNurcin Yilmaz
Nurcin Yilmaz
EDEmine Irem Deveci
Emine Irem Deveci
DCDilek Ozturk Civelek
Dilek Ozturk Civelek
AOAlper Okyar
Alper Okyar
Background: Meloxicam (MLX) is a preferential cyclooxygenase-2 inhibitor widely used in avian medicine as an anti-inflammatory agent. Despite marked interspecific variability in avian drug disposition, no pharmacokinetic data are available for MLX in the white stork ( Ciconia ciconia ). This study aimed to characterise and compare the plasma pharmacokinetics of MLX in this species. Methods: Six clinically stable, non-releasable white storks (three of each sex) received a single 1 mg/kg dose of MLX by the IM, SC and PO routes in a randomised three-way crossover design with a 2-week washout period between treatments. Plasma MLX concentrations were quantified up to 24 h using HPLC and analysed using non-compartmental methods. Results: Peak plasma concentrations (C max ) differed significantly among all three routes (IM 11.49 ± 2.34, SC 6.43 ± 1.62, PO 1.53 ± 0.89 µg/mL; p < 0.05) and the median time to peak concentration (tmax) was progressively delayed from IM (0.67 h) through SC (2.00 h) to PO (4.00 h). Systemic exposure did not differ significantly between the IM and SC routes (AUC 0–24 h 80.7 ± 40.2 and 81.1 ± 22.7 µg·h/mL, respectively) and approximately 7-fold greater than after PO administration (11.9 ± 4.8 µg·h/mL; p < 0.05), corresponding to relative bioavailabilities versus IM of 100.4% for SC and 14.8% for PO. Terminal half-life progressively increased from IM (9.81 ± 2.30 h) through SC (15.13 ± 4.41 h) to PO (18.85 ± 2.16 h). Conclusion: SC administration may represent a practical parenteral alternative to IM, whereas PO administration displayed low and variable bioavailability in white storks.